Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-Label Study of Preflucel (2010/2011 Trivalent Seasonal Influenza Vaccine) in Adults and Elderly
2010-020026-17Phase 3Completed
- Sponsor
- Baxter International Inc.
- Start
- Apr 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of cell culture-derived trivalent subunit influenza vaccine in influenza (2 arms), sponsored by Baxter International Inc. Primary endpoints: Immunogenicity to each of the three influenza antigens and Safety and tolerability. Started Apr 2010; status: completed.
02
Drugs
cell culture-derived trivalent subunit influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2010-020026-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020026-17.